{"id":"NCT04486313","sponsor":"Romark Laboratories L.C.","briefTitle":"Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19","officialTitle":"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-13","primaryCompletion":"2021-02-08","completion":"2021-02-08","firstPosted":"2020-07-24","resultsPosted":"2024-03-29","lastUpdate":"2024-03-29"},"enrollment":935,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Nitazoxanide","otherNames":["NTZ (nitazoxanide)","NT-300"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Vitamin Super B-Complex","otherNames":[]}],"arms":[{"label":"Nitazoxanide","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19","primaryOutcome":{"measure":"Time to Sustained Clinical Recovery","timeFrame":"Up to 21 days","effectByArm":[{"arm":"Nitazoxanide","deltaMin":13.3,"sd":null},{"arm":"Placebo","deltaMin":12.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8786"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["35237748"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":472},"commonTop":["Diarrhoea"]}}